Antony Currie and Robert Cyran explain why Teva's $40 bln unsolicited offer for Mylan looks tricky: antitrust, leverage, a poison pill – and its target's own hostile bid for another rival.
from Reuters Video: Breakingviews http://ift.tt/1HfSCI9
via
IFTTT
No comments:
Post a Comment